GlassScriptPhysician profile
Kelly C Johnson
NPI 1871732503
$9,125.23
in general payments reported to CMS, 2019-2025
48 companies · $1,411 in 2025
The $1,411 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,100 · 2020: $258 · 2021: $756 · 2022: $1,523 · 2023: $2,235 · 2024: $1,843 · 2025: $1,411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,166 · Honoraria: $258 · Education: $65.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,165.53 |
| Honoraria | $257.63 |
| Education | $65.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $1,081.81 | 2023-2025 | Gemtesa, Orgovyx |
| Medtronic, INC. | $1,046.09 | 2022-2025 | Interstim |
| Astellas Pharma US INC | $786.66 | 2019-2024 | Myrbetriq |
| Janssen Biotech, INC. | $627.20 | 2019-2025 | Erleada, Akeega |
| Axonics, INC. | $620.72 | 2021-2024 | Axonics, Bulkamid |
| Urovant Sciences INC | $521.83 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $506.21 | 2019-2025 | Adstiladrin |
| Abbvie INC. | $353.40 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $350.71 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $282.72 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Endo Pharmaceuticals INC. | $280.60 | 2019-2024 | Xiaflex, Aveed |
| Allergan, INC. | $273.58 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $218.65 | 2023-2025 | |
| Endo USA, INC. | $202.18 | 2024-2025 | Xiaflex, Aveed |
| Progenics Pharmaceuticals, INC. | $201.90 | 2023-2025 | Pylarify |
Show all 46 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$361,837.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.